ApconiX Opens a New Office in Sweden

ApconiX is excited to announce the opening of our new office in Sweden.  The subsidiary ApconiX AB will be located at AstraZeneca’s BioVentureHub in Mölndal, Gothenburg. ApconiX was formed by Dr Richard Knight, Dr Michael Morton and Professor Ruth Roberts in 2015 and is based at Alderley Park in Cheshire, U.K.   The co-founders have established [...]

By |2019-02-07T12:13:15+00:00February 7th, 2019|Ion Channels, Target Safety Assessments, Toxicology, Events|Comments Off on ApconiX Opens a New Office in Sweden

Professor Ruth Roberts Hosts ATS Meeting

Professor Ruth Roberts was elected President of the Academy of Toxicology Sciences in June 2018 and holds the position until June 2019.  She will be hosting the ATS Annual Business Meeting and Reception at SOT on Tuesday, March 12 where she will be presenting Dr William Slikker, Jr. with the 2019 Mildred Christian Award at [...]

By |2019-02-06T11:25:46+00:00February 6th, 2019|Toxicology, Events|Comments Off on Professor Ruth Roberts Hosts ATS Meeting

ApconiX Welcomes Dr Steffen Ernst

ApconiX is delighted to welcome Dr Steffen Ernst to our team, as the company begins its international expansion with the formation of its Swedish subsidiary, ApconiX AB. Steffen has worked in preclinical and clinical safety for over 20 years with Hoechst-Schering, Boehringer-Ingelheim, AstraZeneca, Pfizer and Ipsen, holding various pre-clinical and clinical positions of ever-increasing responsibility [...]

By |2019-02-07T16:37:23+00:00February 6th, 2019|Toxicology, Careers|Comments Off on ApconiX Welcomes Dr Steffen Ernst

Study monitoring – why is it important?

Guy Healing, Senior Toxicologist at ApconiX is interviewed by Jon Clements of Metamorphic PR What is study monitoring and why is it important to drug discovery projects? Pharma companies need to ensure their drugs are safe but also that they work. In drug development this requires numerous studies to be presented to international regulators, and [...]

By |2019-02-06T10:00:33+00:00February 6th, 2019|Nonclinical Study Monitoring|Comments Off on Study monitoring – why is it important?

ApconiX Welcomes Steve Snyder

ApconiX is delighted to welcome Steve Snyder to the team.  Steve joins the nonclinical study monitoring team and is based in Florida in the United States. Having worked at Wyeth, Eli Lilly, McNeil Pharmaceutical and Charles River, Steve has a wealth of experience in preclinical toxicology as both an outsourcing customer and provider.  He is [...]

By |2019-02-06T09:53:22+00:00February 6th, 2019|Nonclinical Study Monitoring, Careers|Comments Off on ApconiX Welcomes Steve Snyder

ApconiX Welcomes Dr Bjorn Dahl

ApconiX is delighted to welcome Dr Björn Dahl to the team, who joins our new Swedish office at AstraZeneca’s BioVentureHub in Mölndal, Gothenburg. Björn is a highly respected and experienced toxicologist, having been the co-chair of the European Federation Pharmaceutical Industry Association (EFPIA) Preclinical Development Expert Working Group and served as the EFPIA topic lead [...]

By |2019-02-07T16:37:46+00:00February 6th, 2019|Toxicology, Careers|Comments Off on ApconiX Welcomes Dr Bjorn Dahl

Professor Ruth Roberts Becomes an Honorary Fellow of the British Toxicology Society

ApconiX are delighted to learn that the BTS Executive Committee has elected Professor Ruth Roberts as Honorary Fellow of the British Toxicology Society (hon FBTS) in recognition of her outstanding contribution to the science and profession of Toxicology, including to the BTS. Ruth commented “It’s such an honour to be recognised in this way by [...]

By |2019-01-30T15:27:43+00:00January 31st, 2019|Toxicology, Events, Uncategorised|Comments Off on Professor Ruth Roberts Becomes an Honorary Fellow of the British Toxicology Society

Differential expression of cyclin-dependent kinases in the adult human retina in relation to CDK inhibitor retinotoxicity

Abstract Cyclin-dependent kinases (CDKs) are a family of kinases associated predominantly with cell cycle control, making CDK inhibitors interesting candidates for anti-cancer therapeutics. However, retinal toxicity (loss of photoreceptors) has been associated with CDK inhibitors, including the pan-CDK inhibitor AG-012896. The purpose of this research was to use a novel planar sectioning technique to determine [...]

By |2019-01-30T12:25:18+00:00January 24th, 2019|Toxicology, Publications|Comments Off on Differential expression of cyclin-dependent kinases in the adult human retina in relation to CDK inhibitor retinotoxicity

Phumzile Sikakana Graduates

Phum graduated from the University of Sheffield this month with a master’s degree following research into “The role of the phosphoinositide (PI) 5-kinase PIKfyve in phagosome maturation and killing, using the amoeba and model phagocyte Dictyostelium discoideum”. It was brilliant to hear Phum had been awarded a distinction. Everyone at ApconiX says, “Well Done!”

By |2019-01-16T13:58:58+00:00January 22nd, 2019|Events|Comments Off on Phumzile Sikakana Graduates

ApconiX Awards Prize for Best Toxicology Project

ApconiX is very happy to sponsor the best MSc Toxicology Project prize at the University of Birmingham. This year’s winner was Christopher Cox.  Chris was investigating the mechanisms of toxicity of ferro-nucleobases developed at Birmingham by James Tucker (Professor of Supramolecular Chemistry) in pancreatic ductal adenoma cell lines. (J. Med. Chem., 2014, 57 (13), pp [...]

By |2019-02-06T11:35:21+00:00January 17th, 2019|Events|Comments Off on ApconiX Awards Prize for Best Toxicology Project